Corvus’ seasoned team of biopharma industry leaders are dedicated to developing new medicines for patients in need. Their successful track record of discovering, developing and commercializing innovative therapies for patients with serious diseases includes inventors and scientists who developed the anti-cancer medicines, Rituxan (rituximab), Imbruvica (ibrutinib) and Zelboraf (vemurafenib).
Founded in 2014, Corvus has rapidly developed a deep pipeline of potentially breakthrough investigational medicines designed to be potent, selective and convenient to administer. The pipeline has been expanded through internal discovery and in-licensing and we have efficiently moved our investigational medicines into the clinic, where we are conducting intelligently-designed, rigorously-conducted clinical trials at leading institutions.
